Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma

European Journal of Cancer

Volumn 48, Issue 6, 2012, Pages 896-903

  Brandes, A A ^a   Franceschi, E ^a   Gorlia, T ^b   Wick, W ^c   Jacobs, A H ^d   Baumert, B G ^e   Van Den Bent, M ^f   Weller, M ^g   Stupp, R ^h  

^a MAGGIORE HOSPITAL   (Italy)

^b EORTC DATA CENTER   (Belgium)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

End points; Overall survival; Overall survival rates; Progression free survival; Recurrent glioblastoma

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CEDIRANIB; FLUORINE 18; FOTEMUSTINE; LOMUSTINE; PLACEBO; STEROID; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; CANCER RECURRENCE; DRUG EFFICACY; GLIOBLASTOMA; HUMAN; NEURORADIOLOGY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; BRAIN NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; GLIOBLASTOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE;

EID: 84859107015     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.10.027     Document Type: Article

References (53)

1. D.R. Macdonald, T.L. Cascino, S.C. Schold Jr., and J.G. Cairncross Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 7 1990 1277 1280 (Pubitemid 20195640)
2. P.Y. Wen, D.R. Macdonald, and D.A. Reardon Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group J Clin Oncol 28 11 2010 1963 1972
3. M.J. van den Bent, M.A. Vogelbaum, P.Y. Wen, D.R. Macdonald, and S.M. Chang End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria J Clin Oncol 27 18 2009 2905 2908
4. D.A. Reardon, E. Galanis, and J.F. DeGroot Clinical trial end points for high-grade glioma: the evolving landscape Neuro Oncol 13 3 2011 353 361
5. T.T. Batchelor, A.G. Sorensen, and E. di Tomaso AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 11 1 2007 83 95 (Pubitemid 46075199)
6. C.G. Moertel Improving the efficiency of clinical trials: a medical perspective Stat Med 3 4 1984 455 468
7. E.T. Wong, K.R. Hess, and M.J. Gleason Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials J Clin Oncol 17 8 1999 2572 2578 (Pubitemid 29368260)
8. W.K. Yung, R.E. Albright, and J. Olson A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse Br J Cancer 83 5 2000 588 593 (Pubitemid 30636298)
9. W.K. Yung, M.D. Prados, and R. Yaya-Tur Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group J Clin Oncol 17 9 1999 2762 2771 (Pubitemid 29415233)
10. M. Brada, K. Hoang-Xuan, and R. Rampling Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse Ann Oncol 12 2 2001 259 266 (Pubitemid 32223879)
11. K.A. Jaeckle, W. Wu, M. Kosel, P.J. Flynn, and J.C. Buckner Correlation of response with survival endpoints in patients with newly diagnosed and recurrent glioblastoma (GBM) treated on prospective North Central Cancer Treatment Group (NCCTG) clinical trials Journal of Clinical Oncology 26 S15 2008 2024
12. M. Prados, T. Cloughesy, and M. Samant Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab Neuro Oncol 13 1 2011 143 151
13. D.K. Moscatello, G. Ramirez, and A.J. Wong A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors Cancer Res 57 8 1997 1419 1424 (Pubitemid 27175553)
14. K.R. Lamborn, W.K. Yung, and S.M. Chang Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas Neuro Oncol 10 2 2008 162 170
15. K.V. Ballman, J.C. Buckner, and P.D. Brown The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme Neuro Oncol 9 1 2007 29 38 (Pubitemid 46543486)
16. M.D. Groves, V.K. Puduvalli, and K.R. Hess Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme J Clin Oncol 20 5 2002 1383 1388 (Pubitemid 34177446)
17. A.A. Brandes, U. Basso, and M. Reni First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia J Clin Oncol 22 9 2004 1598 1604 (Pubitemid 41079797)
18. K.A. Jaeckle, K.R. Hess, and W.K. Yung Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study J Clin Oncol 21 12 2003 2305 2311 (Pubitemid 46621868)
19. W. Wick, V.K. Puduvalli, and M.C. Chamberlain J Clin Oncol 2010
20. T. Batchelor, P. Mulholland, and B. Neyns A phase III randomized study comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, with lomustine alone in recurrent glioblastoma patients Ann Oncol 21 Suppl. 8 2010 84
21. A.A. Brandes, A. Tosoni, and E. Franceschi Cancer Chemother Pharmacol 2009
22. J.C. Soria, C. Massard, and T. Le Chevalier Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol 21 12 2010 2324 2332
23. K.S. Panageas, L. Ben-Porat, M.N. Dickler, P.B. Chapman, and D. Schrag When you look matters: the effect of assessment schedule on progression-free survival J Natl Cancer Inst 99 6 2007 428 432 (Pubitemid 47073565)
24. E.D. Saad, A. Katz, P.M. Hoff, and M. Buyse Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature Ann Oncol 21 1 2010 7 12
25. Committee for Medical Products for Human Use. Appendix 1 to the Guideline on the Evaluation of Anticancer Medicinal Products in Man. London, UK: EMEA CPMP/EWP/205/95/Rev 3, 2008.
26. Federal Drug Administration.Guidance for Industry. Clinical Trial end-points for the Approval of Cancer Drugs and Biologics. Rockville, MD: US Department of Health and Human Services In; 2007.
27. H.S. Friedman, M.D. Prados, and P.Y. Wen Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 28 2009 4733 4740
28. W. Wick, M. Weller, M. van den Bent, and R. Stupp Bevacizumab and recurrent malignant gliomas: a European perspective J Clin Oncol 28 12 2010 e188 e189 [author reply e190-2]
29. A.A. Brandes, and E. Franceschi New agents and new end points for recurrent gliomas J Clin Oncol 29 9 2011 e245 e246 [author reply e247]
30. K.A. Carson, S.A. Grossman, J.D. Fisher, and E.G. Shaw Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials J Clin Oncol 25 18 2007 2601 2606 (Pubitemid 47041234)
31. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. In: World Federation of Neuro-Oncology Second Quadrennial Meeting; 2005; Edinburgh, Scotland; 2005. p. Abstract 342.
32. F. Bokstein, S. Shpigel, and D.T. Blumenthal Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors Cancer 112 10 2008 2267 2273 (Pubitemid 351628638)
33. T.F. Cloughesy, M.D. Prados, and P.Y. Wen A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) J Clin Oncol (Meeting Abstracts) 26 Suppl. 15 2008 2010b
34. J.J. Vredenburgh, A. Desjardins, and J.E. Herndon 2nd Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 30 2007 4722 4729 (Pubitemid 350086473)
35. J.J. Vredenburgh, A. Desjardins, and J.E. Herndon 2nd Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Clin Cancer Res 13 4 2007 1253 1259 (Pubitemid 46424067)
36. T.N. Kreisl, L. Kim, and K. Moore Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 27 2008 740 745
37. M.J. van den Bent, A.A. Brandes, and R. Rampling Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034 J Clin Oncol 27 8 2009 1268 1274
38. G. Dresemann, M. Weller, and M.A. Rosenthal Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide J Neurooncol 96 3 2010 393 402
39. D.A. Reardon, G. Dresemann, and S. Taillibert Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma Br J Cancer 101 12 2009 1995 2004
40. W.S. Kamoun, C.D. Ley, and C.T. Farrar Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice J Clin Oncol 27 15 2009 2542 2552
41. P.A. Tang, S.M. Bentzen, E.X. Chen, and L.L. Siu Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy J Clin Oncol 25 29 2007 4562 4568 (Pubitemid 350035313)
42. F. Montagnani, C. Migali, and G. Fiorentini Progression-free survival in bevacizumab-based first-line treatment for patients with metastatic colorectal cancer: is it a really good end point? J Clin Oncol 27 28 2009 e132 e133 [author reply e134-5]
43. A. Ocana, E. Amir, F. Vera, E.A. Eisenhauer, and I.F. Tannock Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions J Clin Oncol 29 3 2010 254 256
44. A.A. Brandes, and E. Franceschi New agents and new end points for recurrent gliomas J Clin Oncol 2010
45. S. Fellah, N. Girard, O. Chinot, P.J. Cozzone, and V. Callot Early evaluation of tumoural response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab J Clin Oncol 29 11 2011 e308 e311
46. A.G. Sorensen, T.T. Batchelor, and W.T. Zhang A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients Cancer Res 69 13 2009 5296 5300
47. 18F] fluorothymidine positron emission tomography: a pilot study J Clin Oncol 25 30 2007 4714 4721 (Pubitemid 350086472)
48. W. Chen Clinical applications of PET in brain tumors J Nucl Med 48 9 2007 1468 1481 (Pubitemid 47397397)
49. 18F- fluoroethyl)-l-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma J Nucl Med 52 6 2011 856 864
50. F.G. Dhermain, P. Hau, H. Lanfermann, A.H. Jacobs, and M.J. van den Bent Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas Lancet Neurol 9 9 2010 906 920
51. 11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma J Nucl Med 50 12 2009 1962 1968
52. T.R. Fleming Standard versus adaptive monitoring procedures: A commentary Stat Med 25 19 2006 3305 3312 [discussion 3313-4, 3326-47] (Pubitemid 44489396)
53. A.E. McKee, A.T. Farrell, R. Pazdur, and J. Woodcock The role of the US Food and Drug Administration review process: clinical trial endpoints in oncology Oncologist 15 Suppl 1 2010 13 18